Abstract
Acral melanoma responds poorly to anti-PD-1 monotherapy. Ori is a HSV-1 derived oncolytic virus expressing granulocyte-macrophage colony-stimulating factor, which has potentiated the efficacy of anti-PD-1 in acral melanoma in the metastatic setting. We conducted a phase Ib trial evaluating ori/tori in resectable stage IIIb-IV (M1a) acral melanoma (NCT04197882).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
